Astellas Pharma Inc (ALPMY) 14.5300 $ALPMY Sanofi's Bid

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 14.5300 $ALPMY

Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation  . Sanofi's purchase price is...
MDVN: 60.10 (+0.03), JNJ: 117.00 (+1.20), GILD: 85.77 (-1.65), SNY: 40.86 (-0.54), NVS: 80.51 (-0.88)

J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 60.10 (+0.03), JNJ: 117.00 (+1.20)

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 60.10 (+0.03), AZN: 28.96 (-0.68), AMAG: 21.86 (-0.24)

Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 60.10 (+0.03), VRX: 25.48 (+1.56)

Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley and Astellas Pharma
ACCESSWIRE - Wed Mar 09, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CUBA Beverage Co. (OTC: CUBV), Arch Therapeutics Inc. (OTC: ARTH), Wolseley PLC (OTC: WOSYY) and Astellas Pharma Inc. (OTC: ALPMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

3 Reasons Medivation, Inc. Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Fri Mar 04, 2:39PM CST
Along with the rest of the healthcare industry,  Medivation   stock has had a rough year, even despite a 10% pop following recently-announced strong fourth-quarter earnings. The boost was especially welcome after the beating Medivation has received...
MDVN: 60.10 (+0.03), JNJ: 117.00 (+1.20)

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 156.78 (-1.22), ANIK: 48.92 (+0.20), CELG: 106.13 (-0.65)

Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 247.40 (-2.55), IRWD: 13.00 (-0.16), AZN: 28.96 (-0.68)

Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 4.55 (-0.13), HZNP: 18.53 (-0.01), LGND: 115.08 (-3.26)

Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused  Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what:  Early in the...
OCAT: 8.47 (+0.01)

Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 247.40 (-2.55), IRWD: 13.00 (-0.16), ACHN: 9.73 (+0.12)

Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 62.53 (-0.54), MYL: 45.76 (-0.75), CORT: 5.47 (-0.17)

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 74.43 (-0.48), EXEL: 7.37 (+0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

Updated Category News Views 11

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Continue Reading
Veterans Transitioning to Real Estate with Scholarships

Updated Category News Views 20

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 27

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Quark Baby's Milk Warmer Debut at Vancouver & Dubai

Updated Category News Views 25

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Continue Reading
Partner Valuation Advisors Bolsters Team with Eichman

Updated Category News Views 9

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Continue Reading
Celebree Gains Franchise Momentum: A New Frontier

Updated Category News Views 17

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Continue Reading
Omneky Outshines Competitors in AI Ad Scoring

Updated Category News Views 34

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 10

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading
Navigating Battery Compliance for AI Data Centers

Updated Category News Views 19

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Continue Reading
AtWork Welcomes Franchise Vet Sarah Goehring

Updated Category News Views 19

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of the Biomarkers Market and Its Growth

Updated Category News Views 139

Biomarkers Market Overview and Growth Potential The global biomarkers market has been experiencing robust growth, with projected valuations reaching US$104.15 billion by 2030. This remarkable advancement reflects a compound annual growth rate (CAGR) of 10.8% from 2025 onward. The increasing integration of biomarkers in drug development and companion diagnostics is a...

Continue Reading
NRI Achieves Cisco Powered Service Designation for SASE Solutions

Updated Category News Views 144

NRI Achieves Managed SASE Cisco Powered Service Designation NRI, a leading business and technology solutions consultancy, has recently achieved an impressive milestone by obtaining the Managed Secure Access Service Edge (SASE) Cisco Powered Service Designation through the Cisco Provider Partner Program. This prestigious recognition showcases NRI's ability to meet the...

Continue Reading
Vaisala Corporation’s Strategic Share Buyback Initiative

Updated Category News Views 92

Understanding Vaisala Corporation's Share Buyback Strategy Vaisala Corporation has made headlines with its recent share buyback initiative, through which it purchased 1,305 shares on August 26, 2025. This move is being seen as a strategic approach to enhance shareholder value. Key Details of the Share Purchase On the Helsinki Stock Exchange, Vaisala executed its share...

Continue Reading
Miami International Holdings Set to Launch Futures Trading Soon

Updated Category News Views 243

Miami International Holdings Plans Financial Futures Launch Miami International Holdings, Inc. (NYSE: MIAX) is gearing up to enhance its trading platform with the introduction of financial futures on MIAX Futures™. This strategic move marks a significant milestone for the company and is anticipated to offer traders new and exciting opportunities. Overview of MIAX...

Continue Reading
Cerence AI and Microsoft Innovate Mobile Work Solutions for Drivers

Updated Category News Views 230

Revolutionizing Mobile Work in the Automotive Industry Cerence AI, a trailblazer in the field of conversational AI, is launching an innovative mobile work AI agent designed for integration within vehicles. This sophisticated technology collaborates with Microsoft 365 Copilot, aiming to transform how professionals interact with their work while on the move. This...

Continue Reading